BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/10/2023 8:15:35 AM | Browse: 144 | Download: 221
 |
Received |
|
2023-07-21 20:38 |
|
Peer-Review Started |
|
2023-07-21 20:40 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-08-23 03:02 |
|
Revised |
|
2023-09-06 15:24 |
|
Second Decision |
|
2023-09-18 02:39 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-09-18 22:24 |
|
Articles in Press |
|
2023-09-18 22:24 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-10-06 13:39 |
|
Publish the Manuscript Online |
|
2023-10-10 08:15 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Response to osimertinib in a colorectal cancer patient with an EGFR T790M mutation: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Blake Buzard, Lindsey Douglass, Beth Gustafson, Jennifer Buckley, Marc Roth, Lara Kujtan and Dhruv Bansal |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Lara Kujtan, MD, Associate Professor, Department of Medical Oncology, University of Missouri - Kansas City, No. 2310 Holmes St, Kansas, MO 64108, United States. kujtanl@umsystem.edu |
| Key Words |
Colorectal cancer; Osimertinib; Epidermal growth factor receptor T790M; Precision oncology; Tyrosine kinase inhibitor; Case report |
| Core Tip |
Somatic epidermal growth factor receptor (EGFR) mutations are rarely found in colorectal cancer. Treatment with anti-EGFR antibodies is commonplace, but EGFR tyrosine kinase inhibitors are not standard in colorectal cancer. Here we report a case of sustained response to osimertinib in a metastatic colorectal cancer patient with an EGFR T790M mutation detected with cell-free DNA. She progressed on three lines of treatment, and received fourth-line treatment with off-label osimertinib, with clinical response. She received treatment with osimertinib for seven months. This case shows the benefit of multi-gene sequencing assays to identify potential therapeutic options in patients with refractory disease. |
| Publish Date |
2023-10-10 08:15 |
| Citation |
Buzard B, Douglass L, Gustafson B, Buckley J, Roth M, Kujtan L, Bansal D. Response to osimertinib in a colorectal cancer patient with an EGFR T790M mutation: A case report. World J Gastrointest Oncol 2023; 15(10): 1829-1834 |
| URL |
https://www.wjgnet.com/1948-5204/full/v15/i10/1829.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v15.i10.1829 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
